Publications by authors named "S Fritchley"
Article Synopsis
- - The study evaluated the effects of intravenous imatinib on patients with acute respiratory distress syndrome (ARDS) caused by COVID-19, focusing on its ability to reduce pulmonary edema.
- - In a randomized trial involving 66 patients, results showed no significant difference in pulmonary edema reduction or clinical outcomes between imatinib and placebo groups, although imatinib was found to be safe.
- - Interestingly, a subset of patients with high levels of specific inflammatory markers did benefit from imatinib treatment, indicating that targeted approaches may improve outcomes in certain ARDS patients.
Article Synopsis
- The CounterCOVID study demonstrated that oral imatinib treatment resulted in improved clinical outcomes and reduced mortality in COVID-19 patients compared to a placebo, with notable elevated levels of alpha-1 acid glycoprotein (AAG) impacting drug concentrations.
- This post-hoc analysis aimed to compare the drug exposure of imatinib in COVID-19 patients versus cancer patients, hypothesizing that higher drug exposure in severe COVID-19 cases would enhance treatment outcomes.
- Results indicated that COVID-19 patients had significantly higher imatinib concentrations than cancer patients, with certain exposure parameters showing significant associations with clinical outcomes, thereby suggesting that higher drug levels could improve recovery metrics in COVID-19 patients.
APT070 inhibits complement activation during in vitro cardiopulmonary bypass.
Eur J Cardiothorac Surg
July 2006
Background: The proteins of the complement cascade play an important role in inflammation and the immune response. They have been shown to be activated during cardiopulmonary bypass (CPB), and may be responsible for the inflammatory response to CPB. We looked at the effect of APT070, an anti-complement agent, on human blood during in vitro CPB.
View Article and Find Full Text PDFDecay-accelerating factor (DAF, CD55) is a glycophosphatidyl inositol-anchored glycoprotein that regulates the activity of C3 and C5 convertases. In addition to understanding the mechanism of complement inhibition by DAF through structural studies, there is also an interest in the possible therapeutic potential of the molecule. In this report we describe the cloning, expression in Escherichia coli, isolation and membrane-targeting modification of the four short consensus repeat domains of soluble human DAF with an additional C-terminal cysteine residue to permit site-specific modification.
View Article and Find Full Text PDFThe chemokines are a family of small chemoattractant proteins that have a range of functions, including activation and promotion of vectorial migration of leukocytes. Regulation on activation, normal T cell expressed and secreted (RANTES; CCL5), a member of the CC-chemokine subfamily, has been implicated in a variety of immune responses. In addition to the interaction of CC-chemokines with their cognate cell-surface receptors, it is known that they also bind to glycosaminoglycans (GAGs), including heparan sulfate.
View Article and Find Full Text PDF